As expected, IL-4 and IL-13 levels were highly increased in ILC2s from PBMCs (IL-4, P<0.0001; IL-13, P<0.0001) (Figures 2D, E) and tumor tissues (IL-4, P<0.0001; IL-13, P<0.0001) (Figures 2F, G) of NSCLC patients than in ILC2s from HD PBMCs. This evidence concerns the gene IL13 and non-small cell lung carcinoma.